This disclosure provides a diagnostic method, which can be used in combination with medical intervention, that uses one or more
plasma biomarkers useful for identifying subjects with
hidradenitis suppurativa (HS), measures the
disease severity of HS, and measures the clinical response in subjects with HS. This disclosure relates to a method for testing for
hidradenitis suppurativa (HS) in a subject, comprising measuring one or more
plasma biomarkers in a sample taken from the subject, wherein one or more
plasma biomarkers are selected from the group consisting of IL8, IL36β, MDC, and TNFα.